Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055108 | 0.89 | MAPT (0.55) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| Ammonia Solution, Strong SCHEMBL4262241 | 0.88 | GUSB (0.49) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL3059494 | 0.87 | GAA (0.53) | MAPTSMN1; SMN2TP53MEN1ALDH1A1 | |
| SCHEMBL3051396 | 0.87 | TP53 (0.55) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL3059036 | 0.83 | TP53 (0.53) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL3055646 | 0.82 | TP53 (0.58) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL6418253 | 0.81 | MAPT (0.50) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL3053645 | 0.81 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| Ammonia Solution, Strong SCHEMBL4270918 | 0.81 | TUBB4A (0.48) | MAPTSMN1; SMN2TP53CCR2CCR5 | |
| SCHEMBL3052141 | 0.80 | KDM4E (0.55) | MAPTSMN1; SMN2TP53CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | claimed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | claimed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | MAPT 3908/4885SMN1; SMN2 243/4885TP53 4/4885 |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | MAPT 3908/4885SMN1; SMN2 243/4885TP53 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.